Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066303 | 0.82 | SMPD3 (0.36) | METAP1 | |
| SCHEMBL354103 | 0.82 | SMPD3 (0.40) | METAP1MEN1KMT2A | |
| SCHEMBL2579053 | 0.81 | CNR2 (0.39) | METAP1MEN1KMT2A | |
| SCHEMBL4409634 | 0.79 | PDE9A (0.35) | MEN1KMT2A | |
| SCHEMBL2066450 | 0.78 | KDM4E (0.53) | — | |
| SCHEMBL353955 | 0.78 | POLB (0.41) | METAP1 | |
| SCHEMBL29195337 | 0.78 | ALDH1A1 (0.37) | GAA | |
| SCHEMBL22031729 | 0.76 | PTPN11 (0.41) | — | |
| SCHEMBL15390619 | 0.74 | GPR119 (0.30) | KMT2A | |
| SCHEMBL15390738 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | claimed |
| WO-2016168992-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2016-10-27 | — | — | WO | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-5639770-A | SUPEROXIDE INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0600092-A1 | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | HTR3A 2905/4885HRH4 849/4885METAP1 3891/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTR3A 2646/4885HRH4 920/4885METAP1 3841/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | HTR3A 2646/4885HRH4 920/4885METAP1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.